In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients
of extreme weights are limited, however, they are still being prescribed in these populations …

Methods We utilized the Health Facts Center National Data Warehouse (Cerner) to perform
a retrospective analysis of patients with VTE (acute deep venous thrombosis (DVT) or …

Extreme obesity—also referred to as severe, grade III, or morbid obesity—is defined as a
body mass index (BMI)> 40 kg/m2, and occurs in 7.7% of the adult US population. 1 This …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …